nach oben

Erschienen in:

02.12.2024 | Originalien

Die häufigsten Fiebersyndrome und autoinflammatorischen Erkrankungen im Erwachsenenalter

verfasst von: Dr. Anne Pankow, Martin Krusche

Erschienen in: Rheuma Plus / Schweiz | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Autoinflammatorische Erkrankungen zeichnen sich durch entzündliche Manifestationen in verschiedenen Organsystemen aus, wobei wiederkehrende Fieberschübe, muskuloskeletale Beschwerden, gastrointestinale und kutane Symptome, begleitet von serologischen Entzündungszeichen, häufig auftreten. Die autoinflammatorischen Erkrankungen umfassen seltene monogenetische Entitäten sowie multifaktorielle/polygene Krankheiten, die sich mit variabler Symptomatik im Laufe der Zeit manifestieren können. Beispiele für monogenetische autoinflammatorische Erkrankungen sind das familiäre Mittelmeerfieber (FMF), das Cryopyrin-assoziierte periodische Syndrom (CAPS), das TNF(Tumor-Nekrose-Faktor)-Rezeptor-assoziierte periodische Syndrom (TRAPS) und das neu beschriebene VEXAS-Syndrom. Bei den nichtmonogenetisch determinierten autoinflammatorischen Erkrankungen sind die wichtigsten Vertreter im Erwachsenenalter die adulte Form der Still-Erkrankung (AOSD) und das Schnitzler-Syndrom, bei denen eher eine polygenetische Suszeptibilität und epigenetische Faktoren eine Rolle spielen.

Vorheriger Artikel Interstitielle Lungenerkrankung bei systemischen autoimmunen rheumatischen Erkrankungen: Update zu Diagnostik und Monitoring

Kotter I, Krusche M (2023) Inflammatory rheumatic diseases in migrants. Inn Med 64(5):426–434. https://doi.org/10.1007/s00108-023-01514-0CrossRef

Ben-Chetrit E, Touitou I (2009) Familial mediterranean Fever in the world. Arthritis Rheum 61(10):1447–1453. https://doi.org/10.1002/art.24458CrossRefPubMed

Bonnekoh H, Butze M, Kallinich T, Kambe N, Kokolakis G, Krause K (2020) Spectrum of Genetic Autoinflammatory Diseases Presenting with Cutaneous Symptoms. Acta Derm Venereol 100(7):adv91. https://doi.org/10.2340/00015555-3427CrossRefPubMed

Kallinich T, Orak B, Wittkowski H (2017) Rolle der Genetik beim familiären Mittelmeerfieber. Z Rheumatol 76:303–312. https://doi.org/10.1007/s00393-017-0265-9CrossRefPubMed

Ozen S, Demirkaya E, Erer B et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651. https://doi.org/10.1136/annrheumdis-2015-208690CrossRefPubMed

Gattorno M, Hofer M, Federici S et al (2019) Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 78(8):1025–1032. https://doi.org/10.1136/annrheumdis-2019-215048CrossRefPubMed

Pankow A, Feist E, Baumann U, Kirschstein M, Burmester GR, Wagner AD (2021) What is confirmed in the treatment of autoinflammatory fever diseases? Internist 62(12):1280–1289. https://doi.org/10.1007/s00108-021-01220-9CrossRefPubMed

Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005. https://doi.org/10.1056/NEJM198604173141601CrossRefPubMed

Levinsky Y, Azani L, Shkalim Zemer V et al (2023) Adherence to colchicine prophylaxis among patients with familial Mediterranean fever treated with interleukin-1 inhibitors. Semin Arthritis Rheum 61:152211. https://doi.org/10.1016/j.semarthrit.2023.152211CrossRefPubMed

10.

Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC (2020) Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 22(1):28. https://doi.org/10.1186/s13075-020-2120-7CrossRefPubMedPubMedCentral

11.

Boyadzhieva Z, Ruffer N, Krusche M (2021) Colchicine: old medication with new benefits : Use in rheumatology and beyond. Z Rheumatol 80(7):647–657. https://doi.org/10.1007/s00393-021-01017-zCrossRefPubMedPubMedCentral

12.

Kallinich T, Blank N, Braun T et al (2019) Evidence-based treatment recommendations for familial Mediterranean fever : A joint statement by the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology. Z Rheumatol 78(1):91–101. https://doi.org/10.1007/s00393-018-0588-1CrossRefPubMed

13.

Cebeci SO, Yildiz M, Gunalp A et al (2023) The efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever. Rheumatol Int. https://doi.org/10.1007/s00296-023-05351-0CrossRefPubMed

14.

Kallinich T, Orak B, Wittkowski H (2017) Role of genetics in familial Mediterranean fever. Z Rheumatol 76(4):303–312. https://doi.org/10.1007/s00393-017-0265-9CrossRefPubMed

15.

Twig G, Livneh A, Vivante A et al (2014) Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann Rheum Dis 73(4):704–709. https://doi.org/10.1136/annrheumdis-2012-202932CrossRefPubMed

16.

Aksentijevich I, Putnam CD, Remmers EF et al (2007) The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 56(4):1273–1285. https://doi.org/10.1002/art.22491CrossRefPubMedPubMedCentral

17.

Hoffman HMK-DJB, Goldbach-Mansky R (2019) Cryopyrine-Associated Periodic Syndromes (CAPS). In: Hashkes PJ, Laxer RM, Simon A (Hrsg) extbook of Autoinflammation. Springer, Berlin/Heidelberg,Germany, S 347–365CrossRef

18.

Krusche M, Kallinich T (2022) Autoinflammation-differences between children and adults. Z Rheumatol 81(1):45–54. https://doi.org/10.1007/s00393-021-01115-yCrossRefPubMed

19.

Rowczenio DM, Gomes SM, Arostegui JI et al (2017) Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism-UK Single Center Experience. Front Immunol 8:1410. https://doi.org/10.3389/fimmu.2017.01410CrossRefPubMedPubMedCentral

20.

Ben-Chetrit E, Gattorno M, Gul A et al (2018) Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis 77(11):1558–1565. https://doi.org/10.1136/annrheumdis-2017-212515CrossRefPubMed

21.

Krause K, Degener F, Altrichter S et al (2010) Cold-induced urticaria and angioedema. Classification, diagnosis and therapy. Hautarzt 61(9):743–749. https://doi.org/10.1007/s00105-010-1932-9CrossRefPubMed

22.

Herbert VG, Ahmadi-Simab K, Reich K, Boer-Auer A (2016) Neutrophilic urticarial dermatosis (NUD) indicating Cryopyrin-associated periodic syndrome associated with a novel mutation of the NLRP3 gene. J Eur Acad Dermatol Venereol 30(5):852–853. https://doi.org/10.1111/jdv.13020CrossRefPubMed

23.

ter Haar NM, Oswald M, Jeyaratnam J et al (2015) Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 74(9):1636–1644. https://doi.org/10.1136/annrheumdis-2015-207546CrossRefPubMed

24.

Welzel T, Kuemmerle-Deschner JB (2021) Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today? J Clin Med. https://doi.org/10.3390/jcm10010128CrossRefPubMedPubMedCentral

25.

Rodriguez-Smith J, Lin YC, Tsai WL et al (2017) Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation. Arthritis Rheumatol 69(6):1325–1336. https://doi.org/10.1002/art.40055CrossRefPubMedPubMedCentral

26.

Putnam CD, Broderick L, Hoffman HM (2023) The discovery of NLRP3 and its function in cryopyrin-associated periodic syndromes and innate immunity. Immunol Rev. https://doi.org/10.1111/imr.13292CrossRefPubMed

27.

Lachmann HJ, Papa R, Gerhold K et al (2014) The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 73(12):2160–2167. https://doi.org/10.1136/annrheumdis-2013-204184CrossRefPubMed

28.

Savic S, Dickie LJ, Battellino M, McDermott MF (2012) Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr Opin Rheumatol 24(1):103–112. https://doi.org/10.1097/BOR.0b013e32834dd2d5CrossRefPubMed

29.

Hull KM, Drewe E, Aksentijevich I et al (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 81(5):349–368. https://doi.org/10.1097/00005792-200209000-00002CrossRefPubMed

30.

De Benedetti F, Gattorno M, Anton J et al (2018) Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med 378(20):1908–1919. https://doi.org/10.1056/NEJMoa1706314CrossRefPubMed

31.

Gattorno M, Obici L, Cattalini M et al (2017) Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis 76(1):173–178. https://doi.org/10.1136/annrheumdis-2015-209031CrossRefPubMed

32.

Gattorno M, Pelagatti MA, Meini A et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58(5):1516–1520. https://doi.org/10.1002/art.23475CrossRefPubMed

33.

Ter Haar N, Lachmann H, Ozen S et al (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72(5):678–685. https://doi.org/10.1136/annrheumdis-2011-201268CrossRefPubMed

34.

Beck DB, Bodian DL, Shah V et al (2023) Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. JAMA 329(4):318–324. https://doi.org/10.1001/jama.2022.24836CrossRefPubMedPubMedCentral

35.

Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 383(27):2628–2638. https://doi.org/10.1056/NEJMoa2026834CrossRefPubMedPubMedCentral

36.

Georgin-Lavialle S, Terrier B, Guedon AF et al (2022) Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol 186(3):564–574. https://doi.org/10.1111/bjd.20805CrossRefPubMed

37.

Ferrada MA, Sikora KA, Luo Y et al (2021) Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis Rheumatol 73(10):1886–1895. https://doi.org/10.1002/art.41743CrossRefPubMed

38.

Tsuchida N, Kunishita Y, Uchiyama Y et al (2021) Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis 80(8):1057–1061. https://doi.org/10.1136/annrheumdis-2021-220089CrossRefPubMed

39.

Muratore F, Marvisi C, Castrignano P et al (2022) VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis. Arthritis Rheumatol 74(4):665–670. https://doi.org/10.1002/art.41992CrossRefPubMedPubMedCentral

40.

Matsumoto H, Asano T, Tsuchida N et al (2022) Behcet’s disease with a somatic UBA1 variant:Expanding spectrum of autoinflammatory phenotypes of VEXAS syndrome. Clin Immunol 238:108996. https://doi.org/10.1016/j.clim.2022.108996CrossRefPubMed

41.

Beck DB, Grayson PC, Kastner DL (2021) Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. Reply. N Engl J Med 384(22):2164–2165. https://doi.org/10.1056/NEJMc2102124CrossRefPubMed

42.

Betrains AJV, Dieudonne Y, Dion J, Lazaro E, De Moreuil C, Ardois S, Grosleron S, Arlet J, Durel C, Delaval L, Audia S, Golden C, Nicolas B, Langlois V, Perlat A, Vandergheynst F, Moulinet T, Samson M, Blockmans D, Kosmider O, Georgin-Lavialle S, Mekinian A, Terrier B Abnormalities Detected with [18F]-FDG-PET/CT Imaging in VEXAS Syndrome [abstract. https://acrabstracts.org/abstract/abnormalities-detected-with-18f-fdg-pet-ct-imaging-in-vexas-syndrome/ (Arthritis Rheumatol 2023;75 (suppl 9))

43.

Casal Moura M, Baqir M, Tandon YK et al (2023) Pulmonary manifestations in VEXAS syndrome. Respir Med 213:107245. https://doi.org/10.1016/j.rmed.2023.107245CrossRefPubMed

44.

Oo TM, Koay JTJ, Lee SF, Lee SMS, Lim XR, Fan BE (2022) Thrombosis in VEXAS syndrome. J Thromb Thrombolysis 53(4):965–970. https://doi.org/10.1007/s11239-021-02608-yCrossRefPubMed

45.

Ruffer N, Krusche M (2023) VEXAS syndrome: a diagnostic puzzle. RMD Open. https://doi.org/10.1136/rmdopen-2023-003332CrossRefPubMedPubMedCentral

46.

Bruno A, Gurnari C, Alexander T et al (2023) Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretation. J Allergy Clin Immunol 151(5):1204–1214. https://doi.org/10.1016/j.jaci.2023.02.017CrossRefPubMed

47.

Gurnari C, Pagliuca S, Durkin L et al (2021) Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood 137(26):3685–3689. https://doi.org/10.1182/blood.2021010811CrossRefPubMedPubMedCentral

48.

Gurnari C, McLornan DP (2022) Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant 57(11):1642–1648. https://doi.org/10.1038/s41409-022-01774-8CrossRefPubMed

49.

Patel BA, Young NS (2022) Towards treatments for VEXAS. Br J Haematol 196(4):804–805. https://doi.org/10.1111/bjh.17930CrossRefPubMed

50.

Boyadzhieva Z, Ruffer N, Kotter I, Krusche M (2023) How to treat VEXAS-Syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology. https://doi.org/10.1093/rheumatology/kead240CrossRefPubMed

51.

Comont T, Heiblig M, Riviere E et al (2022) Azacitidine for patients with Vacuoles, E1 Enzyme, X‑linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol 196(4):969–974. https://doi.org/10.1111/bjh.17893CrossRefPubMed

52.

Diarra A, Duployez N, Terriou L (2021) Mutant UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 384(22):2163–2164. https://doi.org/10.1056/NEJMc2102124CrossRefPubMed

53.

Al-Hakim A, Poulter JA, Mahmoud D et al (2022) Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience. Br J Haematol. https://doi.org/10.1111/bjh.18488CrossRefPubMed

54.

de Valence B, Delaune M, Nguyen Y et al (2023) Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry. Ann Rheum Dis. https://doi.org/10.1136/ard-2023-224819CrossRef

55.

Feist E, Mitrovic S, Fautrel B (2018) Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol 14(10):603–618. https://doi.org/10.1038/s41584-018-0081-xCrossRefPubMedPubMedCentral

56.

Behrens EM, Beukelman T, Gallo L et al (2008) Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 35(2):343–348 (https://www.ncbi.nlm.nih.gov/pubmed/18085728)PubMed

57.

Magadur-Joly G, Billaud E, Barrier JH et al (1995) Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 54(7):587–590. https://doi.org/10.1136/ard.54.7.587CrossRefPubMedPubMedCentral

58.

Gerfaud-Valentin M, Maucort-Boulch D, Hot A et al (2014) Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine 93(2):91–99. https://doi.org/10.1097/MD.0000000000000021CrossRefPubMedPubMedCentral

59.

Church LD, Cook GP, McDermott MF (2008) Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 4(1):34–42. https://doi.org/10.1038/ncprheum0681CrossRefPubMed

60.

Foll D, Wittkowski H, Hinze C (2020) Still’s disease as biphasic disorder : Current knowledge on pathogenesis and novel treatment approaches. Z Rheumatol 79(7):639–648. https://doi.org/10.1007/s00393-020-00779-2CrossRefPubMed

61.

Fautrel B (2008) Adult-onset Still disease. Best Pract Res Clin Rheumatol 22(5):773–792. https://doi.org/10.1016/j.berh.2008.08.006CrossRefPubMed

62.

Crispin JC, Martinez-Banos D, Alcocer-Varela J (2005) Adult-onset Still disease as the cause of fever of unknown origin. Medicine 84(6):331–337. https://doi.org/10.1097/01.md.0000188009.47085.76CrossRefPubMed

63.

Zuelgaray E, Battistella M, de Salle Chou C et al (2018) Increased severity and epidermal alterations in persistent versus evanescent skin lesions in adult-onset Still disease. J Am Acad Dermatol 79(5):969–971. https://doi.org/10.1016/j.jaad.2018.05.020CrossRefPubMed

64.

Nies JF, Schneider U, Krusche M (2022) Rare, rarer, lung involvement in adult-onset Still’s disease: A mini-review. Front Med 9:989777. https://doi.org/10.3389/fmed.2022.989777CrossRef

65.

Kedor C, Tomaras S, Baeumer D, Feist E (2021) Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review. Ther Adv Musculoskelet Dis 13:1759720X211059598. https://doi.org/10.1177/1759720X211059598CrossRefPubMedPubMedCentral

66.

de Koning HD (2014) Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy 4:41. https://doi.org/10.1186/2045-7022-4-41CrossRefPubMedPubMedCentral

67.

Mulla E, Neame R (2015) Delayed development of the IgM paraprotein in Schnitzler’s syndrome. Scand J Rheumatol 44(6):521–522. https://doi.org/10.3109/03009742.2015.1071421CrossRefPubMed

68.

Simon A, Asli B, Braun-Falco M et al (2013) Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy 68(5):562–568. https://doi.org/10.1111/all.12129CrossRefPubMed

69.

Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A (2008) IL‑1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 121(1):260–262. https://doi.org/10.1016/j.jaci.2007.09.021CrossRefPubMed

70.

van Leersum FS, Potjewijd J, van Geel M, Steijlen PM, Vreeburg M (2019) Schnitzler’s syndrome—a novel hypothesis of a shared pathophysiologic mechanism with Waldenstrom’s disease. Orphanet J Rare Dis 14(1):151. https://doi.org/10.1186/s13023-019-1117-2CrossRefPubMedPubMedCentral

71.

Kacar M, Pathak S, Savic S (2019) Hereditary systemic autoinflammatory diseases and Schnitzler’s syndrome. Rheumatology 58(Suppl 6):vi31–vi43. https://doi.org/10.1093/rheumatology/kez448CrossRefPubMedPubMedCentral

72.

Pathak S, Rowczenio DM, Owen RG et al (2019) Exploratory Study of MYD88 L265P, Rare NLRP3 Variants, and Clonal Hematopoiesis Prevalence in Patients With Schnitzler Syndrome. Arthritis Rheumatol 71(12):2121–2125. https://doi.org/10.1002/art.41030CrossRefPubMed

73.

Claes K, Bammens B, Delforge M, Evenepoel P, Kuypers D, Vanrenterghem Y (2008) Another devastating complication of the Schnitzler syndrome: AA amyloidosis. Br J Dermatol 158(1):182–184. https://doi.org/10.1111/j.1365-2133.2007.08251.xCrossRefPubMed

74.

Niederhauser BD, Dingli D, Kyle RA, Ringler MD (2014) Imaging findings in 22 cases of Schnitzler syndrome: characteristic para-articular osteosclerosis, and the “hot knees” sign differential diagnosis. Skelet Radiol 43(7):905–915. https://doi.org/10.1007/s00256-014-1857-yCrossRef

75.

Alix L, Neel A, Cador B et al (2019) Diagnostic value of 18‑F fluorodeoxyglucose PET/CT and bone scan in Schnitzler syndrome. Autoimmunity 52(7-8):264–271. https://doi.org/10.1080/08916934.2019.1680649CrossRefPubMed

76.

Neel A, Henry B, Barbarot S et al (2014) Long-term effectiveness and safety of interleukin‑1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun Rev 13(10):1035–1041. https://doi.org/10.1016/j.autrev.2014.08.031CrossRefPubMed

77.

Krause K, Bonnekoh H, Ellrich A et al (2020) Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome. J Allergy Clin Immunol 145(6):1681–1686 e5. https://doi.org/10.1016/j.jaci.2019.12.909CrossRefPubMed

78.

Lipsker D (2010) The Schnitzler syndrome. Orphanet J Rare Dis 5:38. https://doi.org/10.1186/1750-1172-5-38CrossRefPubMedPubMedCentral

79.

Bonnekoh H, Frischbutter S, Roll S, Maurer M, Krause K (2021) Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study. J Allergy Clin Immunol Pract 9(6):2486–2489 e4. https://doi.org/10.1016/j.jaip.2021.01.024CrossRefPubMed

80.

Paladini A, Vitale A, Frediani B, Cantarini L (2021) Resolution of Schnitzler’s syndrome after haematopoietic stem cell transplantation. Clin Exp Rheumatol 39(3):704. https://doi.org/10.55563/clinexprheumatol/1r3i7iCrossRefPubMed

81.

Levy R, Gerard L, Kuemmerle-Deschner J et al (2015) Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis 74(11):2043–2049. https://doi.org/10.1136/annrheumdis-2013-204991CrossRefPubMed

82.

Yamaguchi M, Ohta A, Tsunematsu T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19(3):424–430 (https://www.ncbi.nlm.nih.gov/pubmed/1578458)PubMed

83.

Kedor CFE Adulter Morbus Still – Neues zur Diagnostik und Therapie – Adult-Onset Still’s Disease: New Developments in Diagnostics and Treatment. Thieme

84.

Vordenbaumen S, Feist E, Rech J et al (2022) DGRh S2e guidelines : Diagnostic and treatment of adult-onset Still’s disease (AOSD). Z Rheumatol 81(Suppl 1):1–20. https://doi.org/10.1007/s00393-022-01276-4CrossRefPubMed

Titel: Die häufigsten Fiebersyndrome und autoinflammatorischen Erkrankungen im Erwachsenenalter
verfasst von: Dr. Anne Pankow
Martin Krusche
Publikationsdatum: 02.12.2024
Verlag: Springer Vienna
Erschienen in: Rheuma Plus / Schweiz / Ausgabe 4/2024
Print ISSN: 3004-9253
Elektronische ISSN: 3004-8931
DOI: https://doi.org/10.1007/s44332-024-00042-9

Editorial

Editorial

» How I treat « – Polyarthrite rhumatoïde précoce et très précoce

Aktuell

„How I treat“ – Die frühe und früheste rheumatoide Arthritis

Rheumatoide Arthritis
Interview

Pulmonale Infiltrate als Erstmanifestation einer Polyarteriitis nodosa (PAN)

Open Access
Kasuistik

Revue de la littérature sur l’arthrite psoriasique et la spondylarthrite axiale

Journal Screen

Éditorial

Editorial

Springer Medizin Österreich

Die häufigsten Fiebersyndrome und autoinflammatorischen Erkrankungen im Erwachsenenalter

Zusammenfassung

Weitere Artikel der Ausgabe 4/2024

Editorial

» How I treat « – Polyarthrite rhumatoïde précoce et très précoce

„How I treat“ – Die frühe und früheste rheumatoide Arthritis

Pulmonale Infiltrate als Erstmanifestation einer Polyarteriitis nodosa (PAN)

Revue de la littérature sur l’arthrite psoriasique et la spondylarthrite axiale

Éditorial

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Editorial

» How I treat « – Polyarthrite rhumatoïde précoce et très précoce

„How I treat“ – Die frühe und früheste rheumatoide Arthritis

Pulmonale Infiltrate als Erstmanifestation einer Polyarteriitis nodosa (PAN)

Revue de la littérature sur l’arthrite psoriasique et la spondylarthrite axiale

Éditorial